NewAmsterdam Pharma N.V. Cash Flow Statement
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
21.58+0.315 (+1.48%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NewAmsterdam Pharma N.V. free cash flow
In fiscal 2025, NewAmsterdam Pharma N.V. generated -$147.8 million of operating cash flow and spent $246,000 on capital expenditures. That left free cash flow of -$148.0 million, a free-cash-flow margin of -657.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
NewAmsterdam Pharma N.V. cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Net Income | -203.82M | -241.60M | -176.94M | -22.63M | -41.78M |
| Net Income growth (YoY) | — | — | — | — | — |
| Depreciation & Amortization | 220.00K | 113.00K | 49.00K | 9.00K | 5.00K |
| Stock-Based Compensation | 59.42M | 33.62M | 24.57M | 4.12M | 1.24M |
| Change in Working Capital | 2.89M | -16.90M | -3.63M | 23.24M | 6.56M |
| Operating Cash Flow | -147.78M | -158.56M | -141.22M | 10.66M | -29.51M |
| Capital Expenditures | -246.00K | -672.00K | -24.00K | -221.00K | -24.00K |
| Investing Cash Flow | -174.92M | -62.85M | -24.00K | -221.00K | -24.00K |
| Financing Cash Flow | 29.52M | 659.51M | 8.91M | 391.90M | 84.70M |
| Net Change in Cash | -293.18M | 438.10M | -132.33M | 402.35M | 55.17M |
| Free Cash Flow | -148.03M | -159.24M | -141.24M | 10.44M | -29.54M |
This table shows 5 annual periods of NewAmsterdam Pharma N.V.'s cash flow statement, from FY 2025 back to FY 2021, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NAMS's reporting calendar. What is a cash flow statement?